JHEP reports : innovation in hepatology · 2026
Spatial profiling defines three immunophenotypes and a perineural invasion-associated immune-evasion niche in gallbladder cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Xing, Yang Xin, Xu Sicheng, He Xinxin, He Gui, Ye Huilin, Zhou Qixian, Ren Junkai, Liu Liqiang, Wang Jie, Peng Yaorong, Zhou Zhenyu, Li Wenbin
Аннотация
BACKGROUND & AIMS: Gallbladder cancer (GBC) has a high risk of postoperative recurrence, and immunotherapy-based adjuvant approaches remain unstandardised. We aimed to define spatial immunophenotypes in GBC and evaluate their associations with clinical outcomes and immune-evasion mechanisms.
METHODS: We used multiplex immunohistochemistry to quantify 16 immune-cell subsets across the tumour core, tumour margin and peritumour regions in 86 treatment-naïve GBCs, and integrated nerve bundle-centred spatial analysis with transcriptomic profiling (n = 9) to investigate perineural invasion (PNI)-associated immune-evasion mechanisms.
RESULTS: Unsupervised clustering and a CD8/α-SMA dual-marker approach defined three spatial immunophenotypes: immune-inflamed, immune-excluded, and immune-desert. The immune-inflamed phenotype featured high intratumoural immune infiltration with elevated PD-L1 expression (median combined positive score: 13.85 vs. 0.41 vs. 0.25, p <0.001), was associated with better prognosis (overall survival [OS]: hazard ratio [HR] 0.25, 95% CI 0.12-0.54, p <0.001; recurrence-free survival [RFS]: HR 0.41, 95% CI 0.21-0.79, p = 0.008), and improved outcomes with adjuvant chemoimmunotherapy vs. chemotherapy alone (OS: HR 0.10, 95% CI 0.02-0.48, p <0.001; RFS: HR 0.29, 95% CI 0.12-0.70, p = 0.003). The immune-excluded phenotype was stroma-enriched (α-SMA, p <0.001), with immune cells largely restricted to the tumour margin or peritumour regions; the immune-desert phenotype showed sparse immune infiltration. PNI was associated with immunosuppressive chronic inflammation, characterised by enrichment of PD-L1+ myeloid cells and exhausted CD8+ T cells near invaded nerve bundles (cell density, p <0.001). Transcriptomic analyses suggested enhanced tumour neurotropism in PNI-positive tumours (gene-set enrichment, p <0.05), together with activation of IL-6/IGF-1 related chronic inflammatory signalling and lipid-metabolic rewiring involving LEP, CD36, and ADIPOQ, collectively shaping a local immune-evasion niche (FDR <0.05).
CONCLUSIONS: We defined three spatial immunophenotypes in GBC with distinct immune features and clinical outcomes. PNI was associated with the formation of a local immune-evasion niche.
IMPACT AND IMPLICATIONS: GBC lacks validated biomarkers to guide postoperative immunotherapy, whereas spatial immune architecture provides a clinically meaningful indicator of tumour immune heterogeneity. By defining three spatial immunophenotypes, we delineate their distinct clinical outcomes and immune-evasion features. Moreover, we demonstrate an association between PNI and the formation of a local immune-evasion niche. These findings may inform clinicians and clinical trialists seeking to optimise postoperative risk stratification and adjuvant treatment strategies, and researchers investigating PNI-related molecular mechanisms. Clinically, integrating spatial immunophenotyping with PNI assessment into routine pathology workflows may improve prognostic stratification and inform adjuvant treatment decisions; however, prospective validation is required before broad clinical adoption.
METHODS: We used multiplex immunohistochemistry to quantify 16 immune-cell subsets across the tumour core, tumour margin and peritumour regions in 86 treatment-naïve GBCs, and integrated nerve bundle-centred spatial analysis with transcriptomic profiling (n = 9) to investigate perineural invasion (PNI)-associated immune-evasion mechanisms.
RESULTS: Unsupervised clustering and a CD8/α-SMA dual-marker approach defined three spatial immunophenotypes: immune-inflamed, immune-excluded, and immune-desert. The immune-inflamed phenotype featured high intratumoural immune infiltration with elevated PD-L1 expression (median combined positive score: 13.85 vs. 0.41 vs. 0.25, p <0.001), was associated with better prognosis (overall survival [OS]: hazard ratio [HR] 0.25, 95% CI 0.12-0.54, p <0.001; recurrence-free survival [RFS]: HR 0.41, 95% CI 0.21-0.79, p = 0.008), and improved outcomes with adjuvant chemoimmunotherapy vs. chemotherapy alone (OS: HR 0.10, 95% CI 0.02-0.48, p <0.001; RFS: HR 0.29, 95% CI 0.12-0.70, p = 0.003). The immune-excluded phenotype was stroma-enriched (α-SMA, p <0.001), with immune cells largely restricted to the tumour margin or peritumour regions; the immune-desert phenotype showed sparse immune infiltration. PNI was associated with immunosuppressive chronic inflammation, characterised by enrichment of PD-L1+ myeloid cells and exhausted CD8+ T cells near invaded nerve bundles (cell density, p <0.001). Transcriptomic analyses suggested enhanced tumour neurotropism in PNI-positive tumours (gene-set enrichment, p <0.05), together with activation of IL-6/IGF-1 related chronic inflammatory signalling and lipid-metabolic rewiring involving LEP, CD36, and ADIPOQ, collectively shaping a local immune-evasion niche (FDR <0.05).
CONCLUSIONS: We defined three spatial immunophenotypes in GBC with distinct immune features and clinical outcomes. PNI was associated with the formation of a local immune-evasion niche.
IMPACT AND IMPLICATIONS: GBC lacks validated biomarkers to guide postoperative immunotherapy, whereas spatial immune architecture provides a clinically meaningful indicator of tumour immune heterogeneity. By defining three spatial immunophenotypes, we delineate their distinct clinical outcomes and immune-evasion features. Moreover, we demonstrate an association between PNI and the formation of a local immune-evasion niche. These findings may inform clinicians and clinical trialists seeking to optimise postoperative risk stratification and adjuvant treatment strategies, and researchers investigating PNI-related molecular mechanisms. Clinically, integrating spatial immunophenotyping with PNI assessment into routine pathology workflows may improve prognostic stratification and inform adjuvant treatment decisions; however, prospective validation is required before broad clinical adoption.